TickerTalks
Browse all tickers →
TickerTalks›$REGN
REREGN

Regeneron Pharmaceuticals, Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 19% YoY at strong marginsCatalyst pendingConsistent chatter on X (2.7K/wk), no spike
$REGN·$68B·Biotechnology·Healthcare
$678.94+2.2%YTD-12.3%1Y+23.9%
Mentions · last 7 days
2026-07-09: 244 posts2026-07-10: 492 posts2026-07-11: 688 posts2026-07-12: 377 posts2026-07-13: 458 posts2026-07-14: 252 posts2026-07-15: 132 posts2,669-4%
Price updated 13h ago·X counts updated 2d ago
REREGN
$REGNRegeneron Pharmaceuticals, Inc.
$678.94+2.18%2.7k posts-4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $REGN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-16

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

15x earnings and 84% gross margins — the July 30 print (with a $1/share IPR&D charge already flagged) sets the tone.

Regeneron Pharmaceuticals is the biotech powerhouse behind Eylea and Dupixent, whose stock is down 14% YTD as the market prices in Eylea biosimilar erosion. Earnings hit in fourteen days with a $127M IPR&D charge already pre-flagged.

  • The core franchise is still a machine: Q1 2026 revenue grew 19% YoY to $3.6B, gross margin held at 81%, and the Dupixent partnership with Sanofi continues to compound — the biosimilar-erosion fear on Eylea is partly offset by Dupixent's expanding indications and by the collaboration pipeline that just triggered the $127M IPR&D charge.
  • Valuation is the setup: 15x trailing earnings and 4.4x sales for a company earning 24% operating margins with a 6.3% FCF yield — the sector-value cohort views Regeneron as a rare 15x + 10%-grower, and Cramer flagged biotech as 'the hottest group' with M&A rumors for founder-led names.
  • Insider action is inconsequential ahead of the print: director Arthur Ryan sold 200 shares at $650 on July 2 for $130K — a trivial print that reads as scheduled distribution, so the setup is decided by the July 30 numbers, not the insider tape.

The July 30 Q2 print is the near-term arbiter — a Q2 EPS beat despite the pre-flagged $1/share IPR&D drag, plus any FY26 revenue guide affirmation, extends the 'value biotech re-rating' setup. A Dupixent miss or Eylea biosimilar penetration accelerating beyond expectations confirms the breaking-Eylea thesis.

Agrees with X sentimentX is bullish framing Regeneron as a 15x P/E, 10% grower core position paired with GILD, with a founder-tenure Celgene/Alexion-style sale on the speculation list. Mechanics support the framing: 15x P/E, 84% gross margin, 6.3% FCF yield, and Q1 revenue +19% YoY. The tension is that Cramer's 'hottest group' framing plus M&A speculation can create over-enthusiasm — the July 30 print has to affirm Dupixent trajectory for the value thesis to hold.

What to watch: The July 30 Q2 earnings. Watch Dupixent revenue growth, Eylea/Eylea HD trajectory against biosimilar entrants, and the impact of the pre-flagged $127M IPR&D charge on non-GAAP EPS. Dupixent affirmation extends the re-rate; softness confirms the biosimilar-erosion thesis.

On the calendar: 2026-07-30 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-07-14

Regeneron chatter highlights the shares up 5-6% from recent adds paired with GILD, with commentators framing REGN as a 15x P/E and 10% growth big-pharma core position and speculating a Celgene/Alexion-style sale is possible given founder tenure. Holders describe additional deep-dive DD on the pipeline and financials, and one Olatorepatide readout note is flagged for adverse-event framing versus Chinese trial conduct.

Read the AI verdict + X sentiment for $REGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Large biopharma with EYLEA (eye disease), Dupixent (atopic dermatitis/asthma), and a broad antibody pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $REGN.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $REGN

Partial — Large biopharma with EYLEA (eye disease), Dupixent (atopic dermatitis/asthma), and a broad antibody pipeline; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
14.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
24.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
14.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
84.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$9.47$8.91+6.3%
Q4 2025Jan 30, 2026$11.44$10.74+6.5%
Q3 2025Oct 28, 2025$11.83$9.65+22.6%
Q2 2025Aug 1, 2025$12.89$8.43+52.9%
Next earningsThu, Jul 30·consensus EPS $10.42

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6B+19.0%81.4%17.8%$6.99$848.3M
Q4 FY25$3.9B+2.5%84.9%22.7%$8.21$922.0M
Q3 FY25$3.8B+0.9%86.1%27.3%$14.09$1.4B
Q2 FY25$3.7B+3.6%85.6%29.4%$13.24$967.6M

Forward consensus

5-year forecast · up to 22 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$15.9B$15.2B – $16.6B$46.15$41.31 – $49.7220
FY27$17.6B$16.4B – $19.2B$53.73$29.90 – $65.4420
FY28$18.9B$18.9B – $18.9B$61.04$49.89 – $74.2922
FY29$20.9B$19.5B – $22.4B$72.36$65.96 – $78.9915
FY30$21.4B$19.9B – $22.9B$71.61$65.28 – $78.1811

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.49%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+5.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-3.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 100.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.245-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Arthur F RyanDirector200 sh$130KSellMay 1Arthur F RyanDirector100 sh$71KSellApr 1Arthur F RyanDirector100 sh$78KSellMar 2Arthur F RyanDirector100 sh$79KSellFeb 19Huda Y ZoghbiDirector1.6K sh$1.3MSellFeb 9Jason PitofskySVP Controller20 sh$16K
+ 2 other (2 exempts) in window

See when $REGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 178-K — Item 5.07: Shareholder vote
AI summary

Regeneron Pharmaceuticals, Inc. held its 2026 annual meeting on June 12, 2026, electing five Class II directors. Joseph Goldstein had the most contested election (72.4M for, 30.9M against); Huda Zoghbi was most broadly supported (100.7M for, 2.7M against). PricewaterhouseCoopers LLP was ratified as auditor (102.5M for, 6.4M against), and executive compensation was approved (96.5M for, 6.9M against). Routine annual governance filing — relatively elevated against-votes for two directors (Goldstein, Christine Poon) merit monitoring but are not unusual for large-cap biotech.

+ 13 other (4 earnings 8-Ks · 2 13Fs · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Regeneron Pharmaceuticals, Inc. Common Stock and Sets a Lead Plaintiff Deadline of September 14, 2026globenewswire.com·17h agoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Regeneron Pharmaceuticals, Inc. Common Stock and Sets a Lead Plaintiff Deadline of September 14, 2026globenewswire.com·17h agoInvestor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuitbusinesswire.com·20h agoWhy Investors Need to Take Advantage of These 2 Medical Stocks Nowzacks.com·8d agoWill Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?zacks.com·10d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$MRNA$SLS$AURA$ATAI$ALLO
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport